Predict your next investment

Asset/Investment Management
imperial.tech

See what CB Insights has to offer

Investments

32

Portfolio Exits

3

Funds

4

Partners & Customers

5

About Imperial Innovations

Imperial Innovations is the technology transfer office for Imperial College London that supports Imperial scientists to commercialize their novel technologies through licensing or company formation. Imperial Innovations is an IP Group plc company.

Imperial Innovations Headquarter Location

London, England,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Imperial Innovations News

Elizabeth Hofheinz, M.P.H., M.Ed. Orthonika: New Spinout From Imperial College London

Nov 16, 2020

• Mon, August 24th, 2015 Wikimedia and Tim1965; Logo courtesy of Orthonika Medicine and engineering have come together again at Imperial Innovations, a UK entity focused on commercializing innovative technologies. They have just launched Orthonika, a spinout company from Imperial College London that is working on the creation of a new knee meniscus replacement. According to the August 3, 2015 news release, “A team of Imperial scientists, led by Professors Andrew Amis (Mechanical Engineering) and Justin Cobb (Surgery & Cancer) have collaborated with Sierra MedTech to design a full substitution system for the knee meniscus. To do this, the scientists studied the structure and function of healthy menisci and applied unique manufacturing technologies to replicate the native structure and organisation of the tissue.” Professors Amis and Cobb will sit on the company’s Board of Directors, alongside Mario Alberto Accardi, Ph.D., Massimiliano Graziosi and Dominique Kleyn from Sierra MedTech, and Tom Buckland from Imperial Innovations. Professor Andrew Amis, co-founder of Orthonika, said in the August 3, 2015 news release “The meniscus has an extremely complex structure and is subject to high stresses. It needs to be both elastic and strong, capable of adapting to an individual’s movement. Our team has studied the structure of a natural meniscus and how it reacts to different forces to design a substitute that would function like a natural meniscus. We have also designed a surgical insertion procedure and related instruments, such as a secure means of fixation to the bone. Commenting on the "unique manufacturing technologies to replicate the native structure and organisation of the tissue, ” Dr. Accardi told OTW, “Orthonika uses state of the art manufacturing capabilities that replicate the three-dimensional organisation and mechanics of native meniscus tissue. Specifically, Orthonika utilises a highly engineered, fibre reinforced design to mimic the complex anisotropic arrangement present within the tissue. By incorporating a fibre reinforced approach, Orthonika aims to manufacture a synthetic meniscus replacement product that mimics the complex mechanical properties of the tissue. Combining this manufacturing capability with the innovative research and experimentation undertaken at Imperial College London, the team has characterised the relationship between meniscus mechanical behaviour and the underlying structure and attachment mechanisms.” “Within the next year, Orthonika will finalise designs for the artificial meniscus and plan for a large animal trial to evaluate device performance in vivo. We are extremely excited about the potential for our technology to provide patients with an alternative solution to traditional meniscus repair strategies and look forward to making formidable progress to move our device closer to the clinic.” The news release stated, “Orthonika is a collaboration with Sierra MedTech, a specialist in the design and fabrication of engineered substrates for use in medicine. Orthonika has been launched through Co.Create, the company formation unit of Imperial Innovations.”

Imperial Innovations Investments

32 Investments

Imperial Innovations has made 32 investments. Their latest investment was in Cagen as part of their Seed on August 8, 2018.

CBI Logo

Imperial Innovations Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/10/2018

Seed

Cagen

Yes

2

2/22/2016

Series A

Precision Ocular

$23.43M

Yes

3

1/12/2016

Series A

import.io

$13M

Yes

2

8/6/2015

Seed

Subscribe to see more

$99M

Subscribe to see more

10

9/1/2010

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/10/2018

2/22/2016

1/12/2016

8/6/2015

9/1/2010

Round

Seed

Series A

Series A

Seed

Seed VC

Company

Cagen

Precision Ocular

import.io

Subscribe to see more

Subscribe to see more

Amount

$23.43M

$13M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

3

2

10

10

Imperial Innovations Portfolio Exits

3 Portfolio Exits

Imperial Innovations has 3 portfolio exits. Their latest portfolio exit was Myotec on December 15, 2010.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/15/2010

Acquired

Undisclosed Investors

1

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

12/15/2010

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Undisclosed Investors

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Imperial Innovations Fund History

4 Fund Histories

Imperial Innovations has 4 funds, including University Challenge Seed Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

University Challenge Seed Fund

UNKNOWN

1

Imperial Innovations Innovation Fund

Subscribe to see more

$99M

10

Apollo Therapeutics Fund

Subscribe to see more

$99M

10

Low Carbon Seed Fund

Subscribe to see more

$99M

10

Closing Date

Fund

University Challenge Seed Fund

Imperial Innovations Innovation Fund

Apollo Therapeutics Fund

Low Carbon Seed Fund

Fund Type

UNKNOWN

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$99M

$99M

$99M

Sources

1

10

10

10

Imperial Innovations Partners & Customers

5 Partners and customers

Imperial Innovations has 5 strategic partners and customers. Imperial Innovations recently partnered with Oxford BioMedica, Cystic Fibrosis Gene Therapy Consortium, and Boehringer Ingelheim on March 3, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

3/14/2019

Partner

Oxford BioMedica, Cystic Fibrosis Gene Therapy Consortium, and Boehringer Ingelheim

United Kingdom, and Germany

Oxford BioMedica : Preliminary Results

In our third partnership agreement of the year , we established a collaboration with the UK Cystic Fibrosis Gene Therapy Consortium , Boehringer Ingelheim and Imperial Innovations to develop a novel inhaled gene therapy for cystic fibrosis .

1

10/1/2018

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

8/6/2018

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

8/6/2018

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/20/2014

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

3/14/2019

10/1/2018

8/6/2018

8/6/2018

5/20/2014

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Oxford BioMedica, Cystic Fibrosis Gene Therapy Consortium, and Boehringer Ingelheim

Country

United Kingdom, and Germany

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Oxford BioMedica : Preliminary Results

In our third partnership agreement of the year , we established a collaboration with the UK Cystic Fibrosis Gene Therapy Consortium , Boehringer Ingelheim and Imperial Innovations to develop a novel inhaled gene therapy for cystic fibrosis .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Imperial Innovations Team

4 Team Members

Imperial Innovations has 4 team members, including current Managing Director, Tony Hickson.

Name

Work History

Title

Status

Tony Hickson

Managing Director

Current

Russ Cummings

Chief Executive Officer, Chief Investment Officer

Former

Susan Searle

Chief Executive Officer

Former

Julian Smith

Chief Financial Officer

Former

Name

Tony Hickson

Russ Cummings

Susan Searle

Julian Smith

Work History

Title

Managing Director

Chief Executive Officer, Chief Investment Officer

Chief Executive Officer

Chief Financial Officer

Status

Current

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.